Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1497-1504

  Oldenhof, John ^a   Hochberg, Marc ^b   Schiff, Michael ^c   Brune, Kay ^d  

^a Kendle Early Stage   (Canada)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Acetaminophen; Aspirin; Ibuprofen; Naproxen sodium; Platelet inhibition; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; NAPROXEN; PARACETAMOL; THROMBOXANE B2;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; ENTERIC COATED TABLET; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THROMBOCYTE AGGREGATION INHIBITION; TOOTH PAIN;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ASPIRIN; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; NONPRESCRIPTION DRUGS; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; YOUNG ADULT;

EID: 77952466833     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.481249     Document Type: Article

References (29)

1. Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005;32:2218-2224
2. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-162
3. Biskupiak JE, Brixner DI, Howard KB, et al. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother 2006;20:7-14
4. Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-473
5. Food and Drug Administration Science Paper. Concomitant use of ibuprofen and aspirin: potential for attenuation of the antiplatelet effect of aspirin. September 8 2006. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM 161282.pdf [Last accessed 11 January 2010]
6. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-1301
7. Catella-Lawson F, Reilly MP, Kapoor SV, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl J Med 2001;345:1809-1817
8. Ouellet M, Percival MD. Mechanism of acetaminophen inhibition of cyclooxy-genase isoforms. Arch Biochem Biophysics 2001;387:273-280
9. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:383-390
10. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008; 59:1058-1073
11. Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 2005;27:185-191
12. Alessandrini P, Avagaro P, Bittolo BG, et al. Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res 1985;37:1-8
13. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 1999;84:404-409
14. Brown N, May JA, Wilcox RG, et al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol 1999;48:57-62
15. Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69:180-186
16. Awtry E, Loscalzo J. Aspirin. Circulation 2000;101:1206-1218
17. Patrono C, Garc?́a Rodr?́guez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383
18. Schiff M, Hochberg MC, Oldenhof J, et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 2009;25:2471-2477
19. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471
20. Capone ML, Tacconelli S, Sciulli MG, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 2007;322:453-460
21. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40: 1109-1120
22. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-346
23. FDA Advisory Committee Background Information, presented to Arthritis Advisory Committee, February 8, 2001. Available at: http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3677b2-01-merck.pdf [Last accessed 11 January 2010]
24. Galliard-Grigioni KS, Reinhart WH. A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 2009;609:96-99
25. Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008;101:1060-1063
26. TM closure times in healthy individuals. Br J Haematol 2005; 130:759-767
27. Von Lewinski F, Riggert J, Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis. J Stroke Cerebrovasc Dis 2009; 18:111-115
28. MacDonald TM, Wei L. Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin Pharmacol Toxicol 2006;98:275-280
29. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with lumiracoxib, ibuprofen, or naproxen. Ann Rheum Dis 2007;66:764-770